Merck Manual

Please confirm that you are a health care professional

honeypot link

Reactive Thrombocytosis (Secondary Thrombocythemia)

By

Jane Liesveld

, MD, James P. Wilmot Cancer Institute, University of Rochester Medical Center

Last full review/revision Sep 2020
Click here for Patient Education
Topic Resources

Reactive thrombocytosis is an elevated platelet count (> 450,000/mcL [> 450,000 × 109/L]) that develops secondary to another disorder.

Some causes of reactive thrombocytosis include

There are also congenital familial thrombocytoses such as those due to thrombopoietin and thrombopoietin receptor gene mutations. For thrombocytosis that is not secondary to another disorder, see Essential Thrombocythemia Essential Thrombocythemia Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or microvascular thrombotic tendency... read more .

Platelet function is usually normal. Unlike in essential thrombocythemia Essential Thrombocythemia Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increased platelet count, megakaryocytic hyperplasia, and a hemorrhagic or microvascular thrombotic tendency... read more , reactive thrombocytosis does not increase the risk of thrombotic or hemorrhagic complications unless patients have severe arterial disease or prolonged immobility.

With secondary thrombocytosis, the platelet count is usually < 1,000,000/mcL (< 1,000,000 × 109/L), and the cause may be obvious from the history and physical examination (perhaps with confirmatory testing). Complete blood count and peripheral blood smear findings may help suggest iron deficiency or hemolysis.

Treatment of the underlying disorder usually returns the platelet count to normal.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read
Test your knowledge
Overview of Thrombotic Disorders
Thrombotic disorders can be caused by genetic defects, which increase the risk of venous thromboembolism, or acquired defects, which increase the risk of arterial and venous thrombosis. Of the acquired causes, which of the following is most likely to increase a patient’s risk of venous thrombosis?
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
 

Also of Interest

 
TOP